STAT3 and plasma cell myeloma: Besides modulating chemoresistance, miR-197-3p targeted Interleukin (IL)-6 and suppressed IL-6/JAK/STAT3 pathways, counteracting the selective proteasome inhibitor Bortezomib’s resistance to multiple myeloma [32].